Interioral Application No PCT/EP2004/050246

A. CLASSII	FICATION OF SUBJEC	T MATTER
IPC 7	A61K31/704	A61P35/00

A61K31/282

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{A61K} & \mbox{A61P} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS, WPI Data

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х,Р	WO 03/082267 A (TURSI JENNIFER MARGARET; FOWST CAMILLA (IT); GERONI MARIA CRISTINA RO) 9 October 2003 (2003-10-09) page 1, paragraph 1 page 4, paragraph 3 - page 4, line 21	1–15
X	"The combination of nemorubicin with cisplatin and mitomycin C is synergistic in experimental tumor models" November 2002 (2002-11), EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, PAGE(S) S20, XP004403486 ISSN: 0959-8049 abstract	1-18

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document, such combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search 20 July 2004	Date of mailing of the International search report 05/08/2004
Name and mailing address of the ISA	Authorized officer

	INTERNATIONAL SEARCH	REPORT	International App	lication No
	•		T/EP200	4/050251
A. CLASSI IPC 7	FICATION OF SUBJECT MATTER A61K31/704			
According to	o International Patent Classification (IPC) or to both national classification	callon and IPC		
B. FIELDS	SEARCHED			
IPC 7	cumentation searched (dassification system followed by classification syst			
Documentat	ion searched other than minimum documentation to the extent that	such documents are inci	aded in the helds se	zarciieo
Electronic d	ata base consulted during the international search (name of data b	ase and, where practical	l, search terms used)
EPO-In	ternal, BIOSIS, WPI Data, PAJ, EMBA	SE	1	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the re	elevant passages		Relevant to claim No.
X	WO 00/38730 A (MASFERRER JAIME L GARY (US); SEARLE & CO (US); KOK () 6 July 2000 (2000-07-06) especially compound C-9 page 47 page 62, line 10 - line 11 page 75, line 3 - page 76, line table 20	I ALANE T		1-45
X Furth	ner documents are listed in the continuation of box C.	χ Patent family (members are listed i	n annex.
*A' docume consid *E' earlier of filing d *L' docume which citation *O' docume other of docume later th	nt which may throw doubts on priority claim(s) or is cited to establish the publication date of another in or other special reason (as specified) and referring to an oral disclosure, use, exhibition or neans and prior to the international filling date but an the priority date claimed	cited to understan invention "X" document of partice cannot be conside involve an invention "Y" document of partice cannot be conside document is comments, such comments, such comments, such comments and comments are document in the art. "&" document member	d not in conflict with ad the principle or the ular relevance; the cered novel or cannot we step when the do- ular relevance; the cered to involve an in- principle with one or mo- principle with one	the application but sory underlying the laimed invention be considered to current is taken alone laimed invention ventive step when the re other such docusto a person skilled lamily
Date of the	actual completion of the international search	I Date of mailing of t	the international sea	rch renord

28/07/2004

Authorized officer

14 July 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2

NI _ 2280 MV Bliswilk

Interional Application No PCT/EP2004/050246

N		In
itegory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	KABUTO M ET AL: "'Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro!" October 1995 (1995-10), NO TO SHINKEI. BRAIN AND NERVE. OCT 1995, VOL. 47, NR. 10, PAGE(S) 969 - 973, XP009033767 ISSN: 0006-8969 abstract	1-3,6-15
	"Preclinical activity against liver metastases of Nemorubicin, a DNA-intercalating cytotoxic agent for the treatment of hepatocellular carcinoma" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11), page S19, XP004403483 ISSN: 0959-8049 abstract	1-14
X	"Properties of the new anthracycline derivative containing modified daunosamine moiety" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11), pages S19-S20, XP004403485 ISSN: 0959-8049 abstract	1-15
X	US 4 672 057 A (BARGIOTTI ALBERTO ET AL) 9 June 1987 (1987-06-09) cited in the application the whole document	1-15
X	US 4 710 564 A (MIZOBUCHI SHIGEYUKI ET AL) 1 December 1987 (1987-12-01) cited in the application the whole document	1-15
х	GB 2 315 067 A (PHARMACIA SPA; PHARMACIA & UPJOHN SPA (IT)) 21 January 1998 (1998-01-21) cited in the application the whole document	1-15
Х	GB 2 296 495 A (PHARMACIA SPA; ERBA CARLO SPA (IT)) 3 July 1996 (1996-07-03) cited in the application the whole document	1-15
	_/	l

.

Intentional Application No
PCT/EP2004/050246

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
ategory °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
,	BONNER J A ET AL: "Doxorubicin decreases the repair of radiation-induced DNA damage" 1990, INTERNATIONAL JOURNAL OF RADIATION BIOLOGY 1990 UNITED KINGDOM, VOL. 57, NR. 1, PAGE(S) 55-64, XP009033771 ISSN: 0020-7616 abstract	1-15
	BONNER J A ET AL: "DOXORUBICIN ENHANCES RADIATION-INDUCED DNA DAMAGE" INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 15, no. SUPPL. 1, 1988, page 163, XP009033770 & 30TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY, NEW ORLEANS, LOU ISSN: 0360-3016 abstract	1-15
	WU LI-TEH: "Doxorubicin as radiation potentiator: Concurrent doxorubicin and radiation therapy interaction and its clinical applications" INFUSION CHEMOTHERAPY: IRRADIATION INTERACTIONS: PRINCIPLES AND APPLICATIONS TO ORGAN SALVAGE AND PREVENTION OF SECOND PRIMARY NEOPLASMS ELSEVIER SCIENCE PUBLISHERS B.V., PO BOX 211, SARA BURGERHARTSTRAAT 25, 1000 AE AMSTERDAM, THE NETHERLANDS; ELSEV, 1998, pages 147-151, XP002289046 ISSN: 0-444-82608-4 the whole document	1-15
	JAGETIA GANESH CHANDRA ET AL: "Effect of doxorubicin on cell survival and micronuclei formation in HeLa cells exposed to different doses of gamma-radiation" STRAHLENTHERAPIE UND ONKOLOGIE, vol. 176, no. 9, September 2000 (2000-09), pages 422-428, XP002289047 ISSN: 0179-7158 abstract	1-15
	CHENOUFI NORCHEN ET AL: "In vitro demonstration of synergy between radionuclide and chemotherapy" JOURNAL OF NUCLEAR MEDICINE, vol. 39, no. 5, May 1998 (1998-05), pages 900-903, XP009033769 ISSN: 0161-5505	1-15

information on patent family members

Internal Application No PCT/EP2004/050246

				I `	TOT/ LI Z	004/ 030240
Patent docu cited in search		Publication date		Patent family member(s)		Publication date
WO 03082	267 A	09-10-2003	WO	03082267	A1	09-10-2003
US 46720!	57 A	09-06-1987	GB	2172594	Α	24-09-1986
			BE	904431	A1	16-07-1986
			BG	60535	B2	28-07-1995
			BR	1100255	A3	02-04-2002
			CZ	9104195	A3	17-03-1993
			DE	3609052	A1	25-09-1986
			HK	37392	Α	04-06-1992
			JР	1791944	С	14-10-1993
			JР	4082160		25-12-1992
			JP	61221194	Α	01-10-1986
			MX	9203114	A1	01-07-1992
US 47105	 64 A	01-12-1987	JP	1049357	В	24-10-1989
			JP	1564850	C	25-06-1990
			JP	61167696	Α	29-07-1986
			JP	62016495	Α	24-01-1987
			ΑT	49412		15-01-1990
			CA	1292225		19-11-1991
			DE	3668173		15-02-1990
			EP	0188293	A1	23-07-1986
GB 23150	67 A	21-01-1998	DE	69710573	D1	28-03-2002
			DE	69710573	T2	31-10-2002
			MO	9802446		22-01-1998
			EP	0889898		13-01-1999
			JP	11513040	T	09-11-1999
GB 22964	95 A	03-07-1996	DE	19547958	 A1	27-06-1996
			ΙT	MI952614	A1	24-06-1996
			JP	8231581	_	10-09-1996